Latest big pharma CFO announces retirement

19 April 2018

A month after US healthcare giant Johnson & Johnson (NYSE: JNJ) announced that its chief financial officer (CFO) Dominic Caruso was to retire after 12 years in the role and Takeda's (TYO: 4502) finance boss left his job with the Japanese firm, France’s biggest pharma company has said that it is losing its long-standing CFO.

Jérôme Contamine is to retire later in 2018 after nine years in the role with Sanofi (Euronext: SAN) and will work with the drugmaker to find his replacement and assist with the transition.

There is likely to be interest among shareholders in France over the nationality of the new CFO. Previously, the company’s appointment of foreign candidates to top positions has not been unanimously popular with its French stakeholders.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK